Lubrizol Corporation has announced a $60-million investment in its LifeSciences business, focusing on new product solutions, capacity expansion, and additional cGMP manufacturing. According to Lubrizol, these investments will strengthen the excipients, polymers, drug formulation and manufacturing, and medical device contract manufacturing capabilities at its facilities.

Additionally, commercial drug product manufacturing will be added at the company’s Particle Sciences facility in Bethlehem, Pennsylvania adjacent to the company’s existing development and clinical trial manufacturing site. The space is expected to be operational in the fourth quarter of 2017 and will accommodate both sterile and non-sterile products, highly potent compounds, and organic solvent processing.

Lubrizol LifeSciences is also investing to expand its global facilities for excipients, polymers. and contract manufacturing. This capital investment will impact multiple sites to increase in-house engineering capacity across the LifeSciences portfolio of medical and pharmaceutical applications.This includes design, manufacturing and sterilization technology for the production of interventional catheters and long-term implantable devices.

Source: Lubrizol